|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||103.55 - 104.87|
|52-week range||59.27 - 104.87|
|PE ratio (TTM)||25.42|
|Earnings date||26 Jan 2018|
|Forward dividend & yield||2.84 (2.71%)|
|1y target est||103.00|
It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014. Globally, the acceptance of marijuana evolved further in 2017 with more countries either legalizing cannabis access at a federal level or exploring the possibility of legalizing cannabis.
Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
Some of the biggest U.S. companies are promising significant annual savings, bigger pension contributions, higher dividend payments and more extensive stock buybacks as executives start to discuss the ...
Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.
Should You Jump on the Marijuana Bandwagon? Investors interested in accessing the marijuana industry have several options. In the US, Scotts Miracle-Gro (SMG) has invested in companies that are positioned to serve the cannabis market.
Should You Jump on the Marijuana Bandwagon? Investing in the marijuana industry—at least in its current stage in the US—certainly comes with its own set of risks. In the preceding part of this series, we discussed how the marijuana plant contains CBD (cannabidiol), which is used for medicinal (XLV) purposes.
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
Investors are fleeing from testosterone drugmaker Lipocine, but its FDA woes portend bigger challenges for companies developing new versions of the embattled hormone.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.